Semaglutide is used in the treatment of type 2 diabetes mellitus. Semaglo is available in pre-filled syringes with the following dosages: 0.25 mg, 0.50 mg, 1 mg, 1.7 mg, and 2.4 mg.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Semaglo Subcutaneous Injection is indicated for:
Semaglo Subcutaneous Injection contains Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 agonists help to:
In case of severe hypoglycemia, have a fast-acting glucose source readily available. If experiencing symptoms like blurred vision, dizziness, or drowsiness due to blood sugar fluctuations, avoid driving or operating machinery until symptoms resolve.
It is not known whether it is safe to consume alcohol with Semaglo Subcutaneous Injection. Please consult your doctor for advice.
Semaglo Subcutaneous Injection may be unsafe to use during pregnancy. Although limited human studies exist, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it. Please consult your doctor.
Information regarding the use of Semaglo Subcutaneous Injection during breastfeeding is not available. Please consult your doctor.
It is not known whether Semaglo Subcutaneous Injection alters the ability to drive. Do not drive or operate machinery if you experience any symptoms that affect your ability to concentrate and react.
Semaglo Subcutaneous Injection is safe to use in patients with kidney disease. No dose adjustment is recommended.
Semaglo Subcutaneous Injection is safe to use in patients with liver disease. No dose adjustment is recommended.
Semaglo is a GLP-1 receptor agonist that reduces blood glucose levels by stimulating insulin secretion and lowering glucagon secretion when blood glucose levels are high. It also delays gastric emptying and reduces appetite, leading to weight loss.
Semaglo Subcutaneous Injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Semaglo contains Semaglutide, a GLP-1 (Glucagon-like Peptide-1) analog. GLP-1 agonists like Semaglutide mimic the incretin hormone GLP-1, which plays several roles in glucose metabolism.
Mechanism of Action:
Indication: Type 2 Diabetes Mellitus
Semaglo is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Hepatic Impairment: No dosage adjustment is required.
Administration Information
Semaglo should be administered once weekly via subcutaneous injection in the abdomen, thigh, or upper arm. The starting dose is 0.25 mg, increased to 0.5 mg after 4 weeks, and can be further increased to 1 mg weekly if needed for glycemic control.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.